Case sudies
 
  • CASE STUDY 1 : LYSINE ACETYLSALICYLATE
 

 

Lysine acetylsalicylate is the active ingredient found in the standard medications Aspegic and Kardegic, available only as a powder for oral or injectable solutions and used for pain control and in the secondary prevention of cardiovascular diseases.

For this active ingredient which has been historically produced in batches, M2i had developed and patented a continuous production process which is innovative, robust and can be scaled up or down.
 
The M2i procedure provides access to a pharmaceutical active ingredient whose properties enable development of novels medications in tablet form.

   

 

 

 

 

 
     
       

 

  • CASE STUDY 2 : CERAMIDES

 

M2i has developed a reliable synthetic platform enabling easier access to compounds of the ceramide, cerebroside, sphingosine and sphingolipid groups by reducing the number of stages and introducing new synthetic intermediates.     

                                                                                              

 
           
   

 

        

 

 

 

  • CASE STUDY 3 : (BROMOMETHYL) CYCLOPROPANE

 

M2i has developed a new production process for (Bromomethyl) cyclopropane that enables us to monitor formation of the critical impurity most difficult to extract by distillation and optimise product stability.

This procedure enables M2i to propose three qualities of (Bromomethyl)cyclopropane at a stability far superior to that of market standards.

(Bromomethyl)cyclopropane is used as a building block in the synthesis of numerous active ingredients.